Skip to main content

Advertisement

Table 5 Postoperative pathologic staging in patients who underwent surgery

From: Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Pathologic stage FEC arm [cases (%)] PE arm [cases (%)] P value
Total 132 130  
pT stage    0.001
 0 11 (8.33) 15 (11.53)  
 DCIS 7 (5.30) 7 (5.38)  
 1 40 (30.30) 62 (47.69)  
 2 57 (43.18) 41 (31.54)  
 3 2 (1.52) 2 (1.54)  
 4 15 (11.36) 3 (2.31)  
pN stage    0.001
 0 46 (34.85) 51 (39.23)  
 1 39 (29.55) 39 (30.00)  
 2 25 (18.94) 18 (13.85)  
 3 22 (16.67) 22 (16.92)  
  1. FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, DCIS ductal carcinoma in situ